The Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in ...

Gilead Sciences has agreed to buy German clinical-stage biotechnology company Tubulis for up to $5 billion in a deal that bolsters the biopharmaceutical company’s oncology pipeline.

Gilead has struck a deal to buy Germany-based Tubulis for $3.15 billion upfront and up to $1.85 billion in milestones, securing an antibody-drug conjugate (ADC) candidate that is racing toward pivotal ...

Gilead Sciences ( GILD) shares snapped a six-session losing streak, closing 0.56% higher at $133.64 on Thursday. The biopharmaceutical company began its downward trend on April 15, and the stock lost ...

Arcus Biosciences (RCUS) stock drops as the company halts a late-stage trial for a lung cancer drug developed with Gilead ...

Gilead Sciences and Arcus Biosciences’ domvanalimab, one of the last anti-TIGIT antibodies still standing, has failed another ...

Gilead Sciences Inc. reports first-quarter earnings Thursday, with investors poised to assess whether the biopharmaceutical ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...

Gilead Sciences agreed to acquire Tubulis GmbH for upwards of $5 billion in a deal that significantly expands Gilead's oncology pipeline and establishes Munich as a dedicated antibody-drug conjugates ...

Arcus Biosciences is discontinuing a phase 3 lung cancer trial it was conducting with Gilead Sciences. Arcus, an oncology company, said Monday it was ending the trial due to futility, meaning it doesn ...